2
Clinical Trials associated with TGFBR-2 KO CD70 CAR NK(The University of Texas MD Anderson Cancer Center) / Not yet recruitingPhase 1IIT Phase 1b Study Of Allogeneic CAR TROP2/IL15 Transduced TGFBR2 KO CB NK-Cells (TRICK-NK) In Combination With Trastuzumab Deruxtecan (T-Dxd) In Treatment-Refractory Breast Cancers
The goal of this clinical research study is to find the highest tolerable dose of TGFBR-2 KO CD70 CAR NK (TRICK-NK) in combination with 2 doses of T-Dxd that can be given to participants who have advanced breast cancer. The safety of TRICK-NK will also be studied.
The goal of Part 1 (dose escalation) of this clinical research study is to find the highest tolerable dose of TRICK-NK (in combination with T-Dxd) that can be given to participants who have advanced breast cancer.
The goal of Part 2 (dose expansion) of this clinical research study is to learn if the dose of TRICK-NK found in Part 1 can help to control the disease.
The optional schedule optimization phase will test a shorter interval between the NK cell infusion and the first dose of T-Dxd.
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
100 Clinical Results associated with TGFBR-2 KO CD70 CAR NK(The University of Texas MD Anderson Cancer Center)
100 Translational Medicine associated with TGFBR-2 KO CD70 CAR NK(The University of Texas MD Anderson Cancer Center)
100 Patents (Medical) associated with TGFBR-2 KO CD70 CAR NK(The University of Texas MD Anderson Cancer Center)
100 Deals associated with TGFBR-2 KO CD70 CAR NK(The University of Texas MD Anderson Cancer Center)